Legislation to create a program for the medicinal use of psilocybin was introduced today in the New Mexico Senate. Senate Bill 219, the Medical Psilocybin Act, would allow those in New Mexico to ...

The Cambridge, Mass., biotechnology company on Thursday said it received a notice of allowance from the U.S. Patent and Trademark Office regarding the drug candidate, ED-003, which is intended to ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Over the last decade, the use of psychedelic substances has evolved from taboo to be considered by many a legitimate ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...